Not so long ago, on 26 Feb 2010 we
started Genelife Clinical Research, after years of planning and analyzing the
cost & expenses. On this day our dreams took-off with a lot of enthusiasm,
promise and hope in the back drop of recession and limited resources. We knew that
if we will survive that period we would have no limits. During those days we
had to survive not only the recession but also against mighty established
players. We survived that period and emerged as a winner in our own way. The
first year was a very emotional year. We had gone through lots of pain and
turbulence before we reached our 1st anniversary. But why I am talking about that
now.. because this was an equally challenging year.
This year we will be remembering as the
year of “reform and regret”. Across the country the quality of care of patients
and clinical research was decreasing considerably. The necessary quality
standards were available as standard in some places and were unavailable in others.
Our regulation which was developed in a piecemeal fashion over a period of time
was not able to manage the things properly and industry was in desperate need
for reform- which finally happened this year. However, the planning, developing
and implementation of this reform took almost a year, which almost killed the
Clinical Research industry of India. Many competitor companies including some
giants pull their curtains down; some changed their mode of operations. This
changed the entire complexion of Clinical Research market, which to some extent
is positive because now only those seriously involved companies are left in
this serious business.
Everybody in healthcare industry was
affected by this “silent” phase and we were no exception. However, with the
confidence in our system and support of clients, friends and well-wishers we
came out of this period. This could have been even better if we would have not
lost some US FDA projects due to this regulatory complication. I still regret
that decision of taking those projects in such an unstable regulatory
environment. It was hard for us, but even larger concern and my deep apology to
those sponsors whose time, energy and money wasted during this tenure.
Since inception, Genelife Clinical
Research has focused on strong customer relationship with a vision "To be
the most respected partner in providing product development and clinical
research needs." The effort of giving the best is a kind of self-motivating
mantra which probably separates us from the rest. And probably this is the only
thing which helps us to emerge excellent from any given situation.
Looking back at the development of
the entire year; it gives me a sense of achievement. We started the year on
high note and anticipated a greater growth; however, with all the hiccups, what
we achieved is remarkable growth not only in terms of project but also in terms
of reach. We now have a global presence and soon we will be operating globally.
We have implemented electronic CRF and looking forward to implement CTMS.
I would like to to attribute this
year’s success to my team, which stuck to the basics & kept me away from
taking any imprudent decisions. The secret of our success this year is not just
doing the right thing but doing the right thing in customer centric way cost
effectively. Very basic principle we understood our sponsor’s requirement and
planned according to their requirement.
On this auspicious occasion, I sincerely
appreciate the faith of clients on our ability. We are looking forward to
deliver that trust in best possible way. I am greatful to all those who have directly
or indirectly helped us to shape our dream and vision. But my greatest thanks
to my colleagues and consultants for their commendable effort and believing the
ideology of Genelife Clinical Research. This year belong to them and I feel
proud to be a part of this excellent team.
I am looking forward for the same
kind of trust, faith and support from everyone in future. I know if we perform
this good, we will evolve even better in the coming year.
Thank You.
Kind Regards,
Dhirendra V. Singh
